Filters: author is Van Schaick [Clear All Filters]
- 1999
Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat,
J Pharm Sci, vol. 88, no. 3, pp. 306-12.
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo,
J Pharmacol Exp Ther, vol. 290, no. 2, pp. 702-9.
- 1998
Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action,
J Pharmacol Exp Ther, vol. 287, no. 1, pp. 21-30.
Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats,
Br J Pharmacol, vol. 124, no. 3, pp. 607-18.
- 1997
Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats,
Br J Pharmacol, vol. 122, no. 3, pp. 525-33.
8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo,
J Pharmacol Exp Ther, vol. 283, no. 2, pp. 800-8.
Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists,
J Pharmacokinet Biopharm, vol. 25, no. 6, pp. 673-94.
Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects,
Naunyn Schmiedebergs Arch Pharmacol, vol. 356, no. 6, pp. 827-37.
- 1996
Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats,
Eur J Pharmacol, vol. 308, no. 3, pp. 311-4.
- 1994
Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat,
J Pharmacol Exp Ther, vol. 268, no. 2, pp. 616-24.
- 1993



